ИННОВАЦИОННЫЕ ТЕХНОЛОГИИ В КАРДИОЛОГИИ: ОТ УДИВЛЕНИЯ К ПРИВЫЧКЕ ИЛИ ЗАБВЕНИЮ
https://doi.org/10.20996/1819-6446-2015-11-4-404-412
Аннотация
Рассматривается изменение «статуса» инновационных технологий в зависимости от полученных доказательств. Представлены примеры, отражающие зарождение интереса в новой технологии лечения, переход из инновационных в стандартные методы лечения, а также ослабление интереса к ранее внедренной технологии в связи с разочаровывающими результатами клинического исследования по оценке его эффективности.
Об авторах
С. Р. Гиляревский
Российская медицинская академия последипломного образования
Россия
Россия
123995, Москва, Баррикадная, 2/1
М. В. Голшмид
Российская медицинская академия последипломного образования
Россия
Россия
123995, Москва, Баррикадная, 2/1
И. М. Кузьмина
Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского
Россия
Россия
129010 Москва, Большая Сухаревская пл., д. 3
Список литературы
1. Anker S.D., Coats A.J., Cristian G., et al. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). Eur Heart J 2015 Jun 16. [Epub ahead of print]
2. Holmes D.R., Reddy V.Y., Turi Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation, a randomized non-inferiority trial. Lancet 2009;374:534-42.
3. Reddy V.Y., Doshi S.K., Sievert H., et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3 year follow-up of the PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Circulation 2013;127:720-9.
4. Reddy V.Y., Holmes D., Doshi S.K., et al. Safety of percutaneous left atrial appendage closure: results from PROTECT AF and the Continued Access Registry. Circulation 2011;123:417-24.
5. Holmes D.R., Kar S., Price M.J., et al. Prospective randomized evaluation for the WATCHMAN left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;64:1-12.
6. Reddy V.Y., Sievert H., Halperin J., et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014;312:1988-98.
7. Gangireddy S.R., Halperin J.L., Fuster V., Reddy V.Y. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. Eur Heart J 2012;33:2700-8.
8. Blackshear J.L., Odell J.A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755-9.
9. Reddy V.Y., Mobius-Winkler S., Miller M.A., et al. Left atrial appendage closure with the WATCHMAN device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study with WATCHMAN Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013;61:2551-6.
10. Fountain R.B., Holmes D.R., Chandrasekaran K., et al. The PROTECT AF (WATCHMAN left atrial appendage system for embolic PROTECTion in patients with atrial fibrillation) trial. Am Heart J 2006;15:956-61.
11. Lewalter T., Kanagaratnam P., Schmidt B., et al. Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion. Europace 2014;16:626-30.
12. Bajaj N.S., Parashar A., Agarwal S., et al. Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a systemic review and analysis of observational studies. J Am Coll Caridol Intv 2014;7: 296-304.
13. Holmes D.R. Jr, Doshi S.K., Kar S., et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol 2015 ;65:2614-23.
14. Mismetti P., Laporte S., Pellerin O., et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA 2015;313:1627-35.
15. Athanasoulis C.A., Kaufman J.A., Halpern E.F., et al. Inferior vena caval filters: review of a 26-year single-center clinical experience. Radiology 2000;216:54-66.
16. Stein P.D., Kayali F., Olson R.E. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 2004;164:1541-5.
17. Hammond C.J., Bakshi D.R., Currie R.J., et al. Audit of the use of IVC filters in the United Kingdom: experience from 3 centres over 12 years. Clin Radiol 2009;64:502-10.
18. Stein P.D., Matta F., Hull R.D. Increasing use of vena cava filters for prevention of pulmonary embolism. Am J Med 2011;124:655-61.
19. Spencer F.A., Bates S.M., Goldberg R.J., et al. A population-based study of inferior vena cava filters in patients with acute venous thromboembolism. Arch Intern Med 2010;170:1456-62.
20. Kearon C., Akl E.A., Comerota A.J., et al.; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in Chest 2012;142:1698-1704]. Chest 2012;141(2 suppl):e419S-494S.
21. Torbicki A., Perrier A., Konstantinides S., et al.; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2276-315.
22. Kaufman J.A., Kinney T.B., Streiff M.B., et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol 2006;17:449-59.
23. Caplin D.M., Nikolic B., Kalva S.P., et al.; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for the performance of inferior vena cava filter placement for the prevention of pulmonary embolism. J Vasc Interv Radiol 2011;22:1499-506.
24. Jaff M.R., McMurtry M.S., Archer S.L., et al.; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011;123:1788-830.
25. Decousus H., Leizorovicz A., Parent F., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep vein thrombosis: Pré vention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409-15.
26. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005;112:416-22.
27. Ansell J. Vena cava filters: do we know all that we need to know? Circulation 2005;112:298-9.
Рецензия
Для цитирования:
Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. ИННОВАЦИОННЫЕ ТЕХНОЛОГИИ В КАРДИОЛОГИИ: ОТ УДИВЛЕНИЯ К ПРИВЫЧКЕ ИЛИ ЗАБВЕНИЮ. Рациональная Фармакотерапия в Кардиологии. 2015;11(4):404-412. https://doi.org/10.20996/1819-6446-2015-11-4-404-412
For citation:
Gilyarevskiy S.R., Golshmid M.V., Kuz'mina I.M. INNOVATIVE TECHNOLOGIES IN CARDIOLOGY: FROM SURPRISE TO HABIT OR FORGETFULNESS. Rational Pharmacotherapy in Cardiology. 2015;11(4):404-412. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-4-404-412
Просмотров:
750
Послать статью по эл. почте 